Tremendous developments are documented in the last two decades in hematology. Systemic application of novel diagnostic technologies and genetic revolution have allowed for the redefining of the molecular mechanisms involved in the pathological transformation of the hematopoietic progenitor cells that permit more precise diagnoses and risk stratifications.
In malignant hematology, toxic, less effective conventional treatment with cytotoxic drugs, radiation and/or hematopoietic stem cell transplantation (HSCT) has been substituting with the concept of ‘personalized medicine’ after understanding of the phenotypic, genetic and molecular characteristics of disorders. Targeted immunotherapy has been a breakthrough approach and has gone through multiple conceptual changes and challenges. Following the spectacular success of passive immunotherapy with monoclonal antibodies, now researchers combine gene therapy and cell therapy that enable reprogramming of the patient’s immune system called as adoptive immunotherapy.
The recent advances in the knowledge about the structure, function and regulation of the coagulation system as well as in the genetic abnormalities in coagulation cascade were important prerequisites for the development of diagnostic tools and therapeutic strategies based on recombinant technology. Similarly, continuous and massive influx of new information regarding the features, biomarkers and underlying mechanisms let to improve treatment strategies, solve therapeutic challenges in benign hematological disorders.
This Research Topic represents a concerted effort to update the community on the new era in haematology. This unique work includes state-of-the-art knowledge in all fields of hematology including recent diagnostic technologies, novel treatment approaches of malign/benign hematological diseases and touch base on unclarified questions. We hope to provide readers a useful resource in the clinical practice and in the development of new research directions.
Categories for submission are as follows:
BENIGN
• Anemias/Pathogenesis-Diagnosis-Treatment
• Neutropenia/Pathogenesis-Diagnosis-Treatment
• Coagulation-Fibrinolysis-Thrombosis-Bleeding
• Bone Marrow Failure
• Transfusion Medicine
MALIGN
• Pathogenesis-Genomics/Proteomics
• New Chemotherapy Approaches-Prognostic Tools
• Stem Cell Transplantation
• Novel Therapeutic Approaches- Adoptive Immunotherapies
• Immunotherapies
Tremendous developments are documented in the last two decades in hematology. Systemic application of novel diagnostic technologies and genetic revolution have allowed for the redefining of the molecular mechanisms involved in the pathological transformation of the hematopoietic progenitor cells that permit more precise diagnoses and risk stratifications.
In malignant hematology, toxic, less effective conventional treatment with cytotoxic drugs, radiation and/or hematopoietic stem cell transplantation (HSCT) has been substituting with the concept of ‘personalized medicine’ after understanding of the phenotypic, genetic and molecular characteristics of disorders. Targeted immunotherapy has been a breakthrough approach and has gone through multiple conceptual changes and challenges. Following the spectacular success of passive immunotherapy with monoclonal antibodies, now researchers combine gene therapy and cell therapy that enable reprogramming of the patient’s immune system called as adoptive immunotherapy.
The recent advances in the knowledge about the structure, function and regulation of the coagulation system as well as in the genetic abnormalities in coagulation cascade were important prerequisites for the development of diagnostic tools and therapeutic strategies based on recombinant technology. Similarly, continuous and massive influx of new information regarding the features, biomarkers and underlying mechanisms let to improve treatment strategies, solve therapeutic challenges in benign hematological disorders.
This Research Topic represents a concerted effort to update the community on the new era in haematology. This unique work includes state-of-the-art knowledge in all fields of hematology including recent diagnostic technologies, novel treatment approaches of malign/benign hematological diseases and touch base on unclarified questions. We hope to provide readers a useful resource in the clinical practice and in the development of new research directions.
Categories for submission are as follows:
BENIGN
• Anemias/Pathogenesis-Diagnosis-Treatment
• Neutropenia/Pathogenesis-Diagnosis-Treatment
• Coagulation-Fibrinolysis-Thrombosis-Bleeding
• Bone Marrow Failure
• Transfusion Medicine
MALIGN
• Pathogenesis-Genomics/Proteomics
• New Chemotherapy Approaches-Prognostic Tools
• Stem Cell Transplantation
• Novel Therapeutic Approaches- Adoptive Immunotherapies
• Immunotherapies
